74%
of retail accounts lose money when trading CFDs with this provider.
Investments involve risks and are not suitable for all investors. CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage.
74%
of retail investor accounts lose money when trading CFDs with this provider.
You should consider whether you understand how CFDs work, and whether you can afford to take the high risk of losing your money.
74%
of retail accounts lose money when trading CFDs with this provider.
Investments involve risks and are not suitable for all investors. CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage.
74%
of retail investor accounts lose money when trading CFDs with this provider.
You should consider whether you understand how CFDs work, and whether you can afford to take the high risk of losing your money.
English (International)
Innoviva Inc
Closed
SectorHealthcare
18.06 0.89
Overview
Share price change
24h
Min
17.74
Max
18.15
Income | 19M 20M |
|---|---|
Sales | 2.3M 92M |
P/E Sector Avg | 50.361 63.778 |
EPS | 0.26 |
Profit margin | 22.147 |
Employees | 127 |
EBITDA | 17M 36M |
Recommendations | Buy |
|---|---|
12 Months Forecast | +206.58% upside |
Next Earnings | 6 May 2025 |
|---|
Market Cap | 7.6M 1.1B |
|---|---|
Previous open | 17.17 |
Previous close | 18.06 |
News Sentiment
By Acuity
72%
28%
353 / 386 Healthcare
Technical Score
By Trading Central
Confidence
Very Strong Bullish Evidence
Innoviva Inc Chart
Past performance is not a reliable indicator of future results.
Related News
Peer Comparison
Price change
Innoviva Inc Forecast
Price Target
By TipRanks
206.58% upside
12 Months Forecast
Average 55 USD 206.58%
High 55 USD
Low 55 USD
Based on 1 Wall Street analysts offering 12 month price targets forInnoviva Inc - Dist in the last 3 months.
Sentiment
By Acuity
353 / 386 Healthcare
News Sentiment
Bearish Evidence
Volatility
Below average
News Volume (RCV)
Below average
Financials
Selling and administration expenses
Operating expenses
Pre-tax profit
Sales
Cost of sales
Gross profit on sales
Interest expense on debt
EBITDA
Operating profit
$
About Innoviva Inc
Innoviva, Inc. engages in the development and commercialization of pharmaceutical products in the United States and internationally. The company's products include RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a LABA, vilanterol (VI), an inhaled corticosteroid (ICS), and fluticasone furoate; ANORO ELLIPTA, a once-daily medicine combining a long-acting muscarinic antagonist (LAMA) and umeclidinium bromide (UMEC) with a LABA, VI; GIAPREZA (angiotensin II), a vasoconstrictor to increase blood pressure in adults with septic or other distributive shock; XERAVA (eravacycline) for the treatment of complicated intra-abdominal infections in adults; and XACDURO, a beta lactamase inhibitor for the treatment of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia. Its development pipeline includes zoliflodacin, a late-stage product candidate, a potential single oral dose cure for the treatment of uncomplicated gonorrhea. Innoviva, Inc. has a strategic partnership with Sarissa Capital Management LP. It has long-acting beta2 agonist (LABA) collaboration agreement with Glaxo Group Limited to develop and commercialize once-daily products for the treatment of chronic obstructive pulmonary disease and asthma. The company was formerly known as Theravance, Inc. and changed its name to Innoviva, Inc. in January 2016. Innoviva, Inc. was incorporated in 1996 and is headquartered in Burlingame, California.
